Phlebolymphology N°65

Venoactive medications and the place of MPFF at a dose of 500 mg in recent guidelines on the management of chronic venous disease

Andrew NICOLAIDES Vascular Screening Diagnostic Centre, Nicosia, Cyprus ABSTRACT Because the venous system is in many respects more complex than the arterial system, because chronic venous disease (CVD) is common in Western populations, and because both specialists and general practitioners have to deal with this disease, there is a need for practical support regarding CVD management in daily practice. This article summarizes the most recent guidelines regarding the place of venoactive drugs (VADs) such as MPFF at a dose of 500 mg in the management of this disease. In addition, it makes suggestions regarding expected improvements in future guideline documents….

Full text

Unmet needs in the assessment of symptoms and signs related to chronic venous disease

Arkadiusz JAWIEN Nicolai Copernicus University Bydgoszcz, Poland ABSTRACT Chronic venous disease (CVD) is a disorder highly prevalent among populations of Western countries and with which both general practitioners and specialists have to deal. It induces pain, causes discomfort, significantly reduces the quality of life for the affected patient, and lacks specific and consensual instruments able to adequately assess its signs and symptoms. This article presents these needs that are still unmet in clinical practice and that relate to the tools currently available for the assessment of the therapeutic efficacy of drugs on the disease symptoms and signs. Suggestions are presented…

Full text

Management of chronic venous disease: the example of MPFF at a dose of 500 mg

Albert Adrien RAMELET Lausanne, Switzerland ABSTRACT Chronic venous disease (CVD) is a common condition and represents a spectrum of disorders. The CEAP classification has been adopted worldwide to facilitate meaningful communication about the disease and to serve as a basis for more scientific analysis of treatment options. In addition to improved methods of defining CVD, there is also now increased understanding of the pathological processes involved in its development. Leukocyte-endothelium interactions are one of the earliest pathophysiological mechanisms at work and appear to be important in many aspects of the disease. The sequence of leukocyte adhesion, endothelial interaction, activation, and…

Full text

Treatment of chronic venous disease of the lower extremities: what’s new in guidelines?

Anthony J. COMEROTA Guidelines for patient care offer recommendations to physicians for diagnosis and management of common diseases that generally apply to the typical patient. This manuscript addresses some of the newer guidelines to help clinicians manage patients with chronic venous disease of the lower extremities. The two important documents, “Management of Chronic Venous Disorders of the Lower Limbs: Guidelines According to Scientific Evidence”1 prepared by an international consensus group under the auspices of the leading societies for venous disease, and, “Antithrombotic Therapy for Venous Thromboembolic Disease,”2 as part of the American College of Chest Physicians (ACCP) 8th consensus conference,…

Full text

Phlebolymphology N° 65 – Editorial

Advances in the Management and Prevention of Chronic Venous Disease Major advances in the management and prevention of chronic venous disease have been made in the last few years. The stimulus has been the realization of the magnitude of the problem and better understanding of the pathophysiology of the condition at the macrocirculatory, microcirculatory, and molecular levels. Although deep vein thrombosis is responsible for some of the most severe forms of chronic venous disease, especially if its treatment is suboptimal, it should be remembered that in most cases, including those with venous ulceration, chronic venous disease is not the result…

Full text

Phlebolymphology N°65 (Vol 16 – N°4 – 2009)

Proceedings of a satellite symposium “Management of chronic venous disease: therapeutic recommendations” XVIth world meeting of the UIP, Monaco , Tuesday September 1st, 2009 EDITORIAL Editorial A. Nicolaides – Phlebolymphology – 2009 ; 16 (4): 312 PHLEBOLOGY Treatment of chronic venous disease of the lower extremities: what’s new in guidelines? A. J. Comerota – Phlebolymphology – 2009; 16 (4): 313 Management of chronic venous disease: the example of MPFF at a dose of 500 mg A. A. Ramelet – Phlebolymphology – 2009; 16 (4): 321 Unmet needs in the assessment of symptoms and signs related to chronic venous disease. A….

Full text